Pleural Effusion Pipeline Analysis Report 2026

Pleural effusion is the abnormal accumulation of fluid in the pleural space surrounding the lungs, impairing respiration. According to Alireza Shirzadi et al., malignancy accounts for about 65.9% of chronic pleural effusion cases, highlighting its significant clinical burden. According to the pleural effusion pipeline analysis, the drug pipeline is expanding with targeted intrapleural therapies and immunotherapy combinations aimed at improving symptomatic relief and reducing invasive procedures. The growing incidence rates, driven by cancer and cardiopulmonary diseases, along with advancements in pleural-directed delivery platforms, are expected to accelerate therapeutic innovation and market growth in the coming years.

Report Coverage

The Pleural Effusion Pipeline Analysis Report gives comprehensive insights into pleural effusion therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for pleural effusion. The pleural effusion report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The pleural effusion pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with pleural effusion treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to pleural effusion.

Pleural Effusion Pipeline Outlook

Pleural effusion is the abnormal accumulation of excess fluid within the pleural cavity, the space between the lungs and chest wall. It occurs when fluid production exceeds absorption due to conditions such as infection, malignancy, heart failure, or inflammation. Increased vascular permeability or impaired lymphatic drainage leads to progressive fluid buildup, causing dyspnea, chest pain, and reduced lung expansion.

Pleural effusion treatment focuses on relieving symptoms and addressing the underlying cause. Management includes thoracentesis, chest tube drainage, antibiotics for infection, diuretics for heart failure, and surgical intervention in complicated or recurrent cases. In November 2020, Taiho Pharmaceutical Co., Ltd. entered into an exclusive license agreement with Lung Therapeutics, Inc. for LTI-01 in Japan. LTI-01, a recombinant human single-chain urokinase plasminogen activator, is being developed to promote fibrinolysis and improve drainage in patients with loculated pleural effusions, addressing a significant unmet therapeutic need.

Pleural Effusion Epidemiology

The pipeline is gaining momentum, supported by a rising disease burden and significant unmet clinical needs. According to Alireza Shirzadi et al., 2025, malignancy accounts for 65.9% of chronic pleural effusion cases. As per published estimates, over 1.5 million patients are affected annually in the United States. Malignant pleural effusion impacts up to 15% of patients with cancer, with approximately 150,000 new cases in the United States and 100,000 in Europe each year. The limited survival rates of 3 to 12 months reinforce the urgency for targeted therapeutic advancements and improved disease management strategies.

Pleural Effusion - Pipeline Therapeutic Assessment

This section of the report covers the analysis of pleural effusion drug candidates based on several segmentations, including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase:

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

The pleural effusion pipeline analysis report covers 50+ drug analyses based on drug classes:

• Small Molecules
• Monoclonal Antibodies
• Immunotherapies
• Peptides
• Vaccines

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration:

• Oral
• Parenteral
• Others

Pleural Effusion Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I covers a major share of the total pleural effusion clinical trials, accounts for 36%, reflecting strong early-stage clinical expansion and active safety profiling. Phase II holds 36%, indicating advancing efficacy validation and dose optimization. Early phase I represents 14%, supporting innovative molecule entry. Phase III comprises 10%, strengthening late-stage confirmation. Phase IV contributes 5%, enhancing post-marketing surveillance and long-term therapeutic confidence.

Pleural Effusion Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the pleural effusion pipeline analysis include small molecules, monoclonal antibodies, immunotherapies, peptides, and vaccines. The pleural effusion report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for pleural effusion. Immune checkpoint inhibitors represent a significant drug class in the pipeline, particularly for malignant pleural mesothelioma-associated effusion. In September 2024, the United States Food and Drug Administration (FDA) approved Pembrolizumab in combination with chemotherapy for unresectable advanced or metastatic malignant pleural mesothelioma. This approval highlights the growing role of immuno-oncology therapies in improving survival outcomes and indirectly managing malignant pleural effusion by controlling underlying tumor progression.

Pleural Effusion Clinical Trials - Key Players

The report for the pleural effusion pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed pleural effusion therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in pleural effusion clinical trials:

• Wuhan YZY Biopharma Co., Ltd.
• Suzhou Maximum Bio-tech Co., Ltd.
• Jiangsu Simcere Pharmaceutical Co., Ltd.
• Jemincare
• Miltenyi Biotec, Inc.
• Iovance Biotherapeutics, Inc.
• Rein Therapeutics
• Clover Biopharmaceuticals AUS Pty
• Genentech, Inc.
• Biogen

Pleural Effusion - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for pleural effusion. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of pleural effusion drug candidates.

Drug: M701

M701 is a recombinant anti-EpCAM × CD3 bispecific antibody that is being administered via pleural infusion to treat malignant pleural effusions caused by NSCLC. Sponsored by Wuhan YZY Biopharma Co., Ltd., the Phase Ib/II study is evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy. M701 is engaging CD3-positive T cells and redirecting them toward EpCAM-expressing tumor cells, activating cytotoxic immune responses. The Phase II portion is comparing M701 with cisplatin or pleural drainage, assessing ORR and Puncture-Free Survival. The study is being completed in October 2026.

Drug: MT027

MT027 is a CRISPR-Cas9 engineered CAR-T cell therapy targeting B7H3-overexpressing malignant pleural tumors. Sponsored by Suzhou Maximum Bio-tech Co., Ltd., this Phase I, open-label, dose-escalation study is evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, and determining the recommended Phase II dose. MT027 is being administered via intrapleural injection through pleural cavity puncture, enabling locoregional delivery to enhance tumor cell clearance. The study is recruiting patients previously treated with standard therapies and is estimated to reach primary completion in May 2026, with overall study completion anticipated in February 2029.

Drug: JMKX000197

JMKX000197 Injection is being evaluated in a Phase Ib, open-label, multicenter study sponsored by Jemincare for the treatment of malignant pleural effusion (MPE). The study assesses safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in approximately 30 patients. JMKX000197 is an investigational injectable therapy administered alongside tube thoracostomy drainage. The trial is starting in December 2024 and is expected to reach primary completion by December 2025, with overall study completion anticipated in November 2026.

Key Questions Answered in the Pleural Effusion Pipeline Insight Report

• Which companies/institutions are leading the pleural effusion drug development?
• Which company is leading the pleural effusion pipeline development activities?
• What is the current pleural effusion commercial assessment?
• What are the opportunities and challenges present in the pleural effusion pipeline landscape?
• What is the efficacy and safety profile of pleural effusion pipeline drugs?
• Which company is conducting major trials for pleural effusion drugs?
• Which companies/institutions are involved in pleural effusion collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in pleural effusion?

Reasons To Buy This Report

The Pleural Effusion Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for pleural effusion. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into pleural effusion collaborations, regulatory environments, and potential growth opportunities.